Juvenescence joins Banco Português de Fomento and 200M Fund in co-investment in Chrysea Laboratories
Retrieved on:
Friday, June 10, 2022
RAMSEY, ISLE OF MAN, June 10, 2022 /PRNewswire/ -- Juvenescence Limited ("Juvenescence"), through its JuvLife Division, joins the 200M Fund portfolio, managed by Banco Portugus de Fomento, in the Venture Round investment in Chrysea Labs ("Chrysea"), a synthetic biology company developing high-value and difficult to source natural products, using proprietary synthetic biology platforms.
Key Points:
- RAMSEY, ISLE OF MAN, June 10, 2022 /PRNewswire/ -- Juvenescence Limited ("Juvenescence"), through its JuvLife Division, joins the 200M Fund portfolio, managed by Banco Portugus de Fomento, in the Venture Round investment in Chrysea Labs ("Chrysea"), a synthetic biology company developing high-value and difficult to source natural products, using proprietary synthetic biology platforms.
- Juvenescence and Chrysea will collaborate to develop and commercialise one of Chrysea's products.
- Banco Portugus de Fomento invested 3.7 million euros (3,721,387.04) in Chrysea, through the 200M Co-investment Fund.
- For Beatriz Freitas, CEO of Banco Portugus de Fomento, the managing entity of the 200M Fund, "it is with great enthusiasm that the 200M Fund supports Chrysea's project of developing precision nutritional products supported by rigorous clinical research, aimed at supporting successful ageing and a healthy lifespan.